Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedernews.google.com
"pamiparib" - Google News
Get the latest updates from "pamiparib" - Google News directly as they happen.
Follow now < 10 followers
Latest posts
Last updated about 2 years ago
BeiGene (NASDAQ:BGNE) Downgraded by SVB Leerink to Market Perform - MarketBeat
about 2 years ago
BeiGene (NASDAQ:BGNE) Downgraded by SVB Leerink to Market Perform MarketBeat
BeiGene and Medison Announce A - GuruFocus.com
about 2 years ago
BeiGene and Medison Announce A GuruFocus.com
BeiGene and Medison Announce Approval and National Reimbursement in Israel for BRUKINSA® (zanubrutinib) for the Treatment of Waldenström's Macroglobulinemia - Stockhouse
about 2 years ago
BeiGene and Medison Announce Approval and National Reimbursement in Israel for BRUKINSA®...
BeiGene and Medison Announce Approval and National Reimbursement in Israel for BRUKINSA® (zanubrutinib) for the Treatment of Waldenström's Macroglobulinemia - Galveston County Daily News
about 2 years ago
BeiGene and Medison Announce Approval and National Reimbursement in Israel for BRUKINSA®...
BeiGene and Medison Announce Approval and National Reimbursement in Israel for BRUKINSA® (zanubrutinib) f - Benzinga
about 2 years ago
BeiGene and Medison Announce Approval and National Reimbursement in Israel for BRUKINSA®...
BeiGene and Medison Announce Approval and National Reimbursement in Israel for BRUKINSA® (zanubrutinib) for the Treatment of Waldenström's Macroglobulinemia - Marketscreener.com
about 2 years ago
BeiGene and Medison Announce Approval and National Reimbursement in Israel for BRUKINSA®...
China NMPA Approves Tislelizumab for Patients with Microsatellite Instability-High or Mismatch Repair-Defi ... - Headlines of Today
about 2 years ago
China NMPA Approves Tislelizumab for Patients with Microsatellite Instability-High or Mismatch Repair-Defi...
China NMPA Approves Tislelizumab for Patients with Microsatellite Instability-High or Mismatch Repair-Deficient Solid Tumors - Stockhouse
about 2 years ago
China NMPA Approves Tislelizumab for Patients with Microsatellite Instability-High or Mismatch Repair-Deficient...
China NMPA Approves Tislelizumab for Patients with Microsatellite Instability-High or Mismatch Repair-Deficient Solid Tumors - StreetInsider.com
about 2 years ago
China NMPA Approves Tislelizumab for Patients with Microsatellite Instability-High or Mismatch Repair-Deficient...
China NMPA Approves Tislelizumab for Patients with Microsatellite Instability-High or Mismatch Repair-Deficient Solid Tumors - Maryville Daily Times
about 2 years ago
China NMPA Approves Tislelizumab for Patients with Microsatellite Instability-High or Mismatch Repair-Deficient...
China NMPA Approves Tislelizumab for Patients with Microsatellite Instability-High or Mismatch Repair-Deficient Solid Tumors - Bluefield Daily Telegraph
about 2 years ago
China NMPA Approves Tislelizumab for Patients with Microsatellite Instability-High or Mismatch Repair-Deficient...
China NMPA Approves Tislelizumab for Patients with Microsatellite Instability-High or Mismatch Repair-Deficient Solid Tumors - Business Wire
about 2 years ago
China NMPA Approves Tislelizumab for Patients with Microsatellite Instability-High or Mismatch Repair-Deficient...